Investor · 1 deal
Every published round Symbiosis Group Limited took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Spinifex Pharmaceuticals | Unnamed stage | Jul 2005 | $3.2m | Participant | bionity.com, GBS Ventures (30 Jun 2015), clinicalleader.com, GBS Ventures (3 Aug 2006), GBS Ventures (26 Jul 2005) |
Companies Symbiosis Group Limited has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | UQ spin-out sold to Novartis in 2015 | Jul 2005 | 1 | 0 |
Fund closes reported for Symbiosis Group Limited, as distinct from the investments it has made.
Companies Symbiosis Group Limited has backed that another company then bought. An exit for the holding, not a deal Symbiosis Group Limited did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | Novartis International | Acquisition | 29 Jun 2015 | US$200m+ (A$260m+) |
| Spinifex Pharmaceuticals | Novartis | Acquisition | 29 Jun 2015 | US$700m (A$911m) |
Stories naming Symbiosis Group Limited. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Spinifex Pharmaceuticals won a $1.67 million federal Commercial Ready grant to advance its neuropathic pain drug, after a $3.25 million syndicate raise the previous July; it was spun out of the University of Queensland.
University of Queensland spinout Spinifex Pharmaceuticals landed $3.25 million from Symbiosis, GBS Venture Partners and Uniseed to advance its neuropathic pain therapy toward toxicology testing.
Also GBS Ventures·GBS Ventures·clinicalleader.com·bionity.com